Becton Dickinson & Co. (BDX) Set to Announce Quarterly Earnings on Tuesday
Becton Dickinson & Co. (NYSE:BDX) is set to release its earnings data on Tuesday, November 5th. Investors that are interested in registering for the company’s conference call can do so using this link.
Shares of Becton Dickinson & Co. (NYSE:BDX) opened at 105.17 on Monday. Becton Dickinson & Co. has a one year low of $74.18 and a one year high of $106.99. The stock has a 50-day moving average of $102.3 and a 200-day moving average of $99.93. The company has a market cap of $20.425 billion and a P/E ratio of 14.10.
A number of research firms have recently commented on BDX. Analysts at SunTrust initiated coverage on shares of Becton Dickinson & Co. in a research note to investors on Friday, October 11th. They set a “buy” rating on the stock. On the ratings front, analysts at Zacks reiterated a “neutral” rating on shares of Becton Dickinson & Co. in a research note to investors on Wednesday, September 25th. They now have a $106.00 price target on the stock. Finally, analysts at Piper Jaffray Cos. upgraded shares of Becton Dickinson & Co. from a “neutral” rating to an “overweight” rating in a research note to investors on Wednesday, September 18th. They now have a $117.00 price target on the stock, up previously from $91.00. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $103.04.
Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.